138 related articles for article (PubMed ID: 21633912)
21. Therapeutic inhibition of tyrosine kinases in systemic sclerosis: a review of published experience on the first 108 patients treated with imatinib.
Bournia VK; Evangelou K; Sfikakis PP
Semin Arthritis Rheum; 2013 Feb; 42(4):377-90. PubMed ID: 22789835
[TBL] [Abstract][Full Text] [Related]
22. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial.
Gordon J; Udeh U; Doobay K; Magro C; Wildman H; Davids M; Mersten JN; Huang WT; Lyman S; Crow MK; Spiera RF
Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-189-93. PubMed ID: 25152211
[TBL] [Abstract][Full Text] [Related]
23. [Efficacy of beraprost sodium on Raynaud's phenomenon in patients with systemic sclerosis].
Kaburaki J; Kuwana M; Akizuki M; Takano M; Tojo T
Nihon Rinsho Meneki Gakkai Kaishi; 1995 Feb; 18(1):29-35. PubMed ID: 7553036
[TBL] [Abstract][Full Text] [Related]
24. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
Abou-Raya A; Abou-Raya S; Helmii M
J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
[TBL] [Abstract][Full Text] [Related]
25. Thermographic and symptomatic effect of a single dose of sildenafil citrate on Raynaud's phenomenon in patients with systemic sclerosis: a potential treatment.
Kumar N; Griffiths B; Allen J
J Rheumatol; 2006 Sep; 33(9):1918-9. PubMed ID: 16960964
[No Abstract] [Full Text] [Related]
26. Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center.
Pope J; McBain D; Petrlich L; Watson S; Vanderhoek L; de Leon F; Seney S; Summers K
Arthritis Rheum; 2011 Nov; 63(11):3547-51. PubMed ID: 21769850
[TBL] [Abstract][Full Text] [Related]
27. Imatinib and the treatment of fibrosis: recent trials and tribulations.
Gordon J; Spiera R
Curr Rheumatol Rep; 2011 Feb; 13(1):51-8. PubMed ID: 21086081
[TBL] [Abstract][Full Text] [Related]
28. Is IL-4 a potential therapeutic target in systemic sclerosis-associated pulmonary fibrosis?
Sfikakis PP
Clin Immunol; 2011 Dec; 141(3):240-1. PubMed ID: 21996458
[No Abstract] [Full Text] [Related]
29. Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosis.
Divekar AA; Khanna D; Abtin F; Maranian P; Saggar R; Saggar R; Furst DE; Singh RR
Clin Immunol; 2011 Dec; 141(3):293-303. PubMed ID: 22015344
[TBL] [Abstract][Full Text] [Related]
30. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial.
Spiera RF; Gordon JK; Mersten JN; Magro CM; Mehta M; Wildman HF; Kloiber S; Kirou KA; Lyman S; Crow MK
Ann Rheum Dis; 2011 Jun; 70(6):1003-9. PubMed ID: 21398330
[TBL] [Abstract][Full Text] [Related]
31. A potential role for imatinib and other small molecule tyrosine kinase inhibitors in the treatment of systemic and localized sclerosis.
Bibi Y; Gottlieb AB
J Am Acad Dermatol; 2008 Oct; 59(4):654-8. PubMed ID: 18571768
[TBL] [Abstract][Full Text] [Related]
32. Tyrosine kinase inhibitor therapy for systemic sclerosis: Quo Vadis?
Mendoza FA; Jiménez SA
Arthritis Rheum; 2011 Nov; 63(11):3199-203. PubMed ID: 21769846
[No Abstract] [Full Text] [Related]
33. Antifibrotic effect after low-dose imatinib mesylate treatment in patients with nephrogenic systemic fibrosis: an open-label non-randomized, uncontrolled clinical trial.
Elmholdt TR; Buus NH; Ramsing M; Olesen AB
J Eur Acad Dermatol Venereol; 2013 Jun; 27(6):779-84. PubMed ID: 22188390
[TBL] [Abstract][Full Text] [Related]
34. Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease.
Distler JH; Manger B; Spriewald BM; Schett G; Distler O
Arthritis Rheum; 2008 Aug; 58(8):2538-42. PubMed ID: 18668536
[TBL] [Abstract][Full Text] [Related]
35. Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials.
Iwamoto N; Distler JH; Distler O
Curr Rheumatol Rep; 2011 Feb; 13(1):21-7. PubMed ID: 21042889
[TBL] [Abstract][Full Text] [Related]
36. Influence of bosentan on fingertip rewarming in patients with systemic sclerosis.
Autenrieth J; Riemekasten G; Bert C; Worm M
J Dtsch Dermatol Ges; 2013 Apr; 11(4):356-9. PubMed ID: 23419126
[No Abstract] [Full Text] [Related]
37. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of imatinib mesylate in systemic sclerosis. A systematic review and meta-analysis.
Liakouli V; Ciaffi J; Ursini F; Ruscitti P; Meliconi R; Ciccia F; Cipriani P; Giacomelli R
Expert Rev Clin Immunol; 2020 Sep; 16(9):931-942. PubMed ID: 32893688
[TBL] [Abstract][Full Text] [Related]
39. Correlations between changes in cytokines and clinical outcomes for early phase (proof of concept) trials in active diffuse systemic sclerosis using data from an imatinib study.
Pope J; Walker KM; de Leon F; Vanderhoek L; Seney S; Summers KL
Rheumatology (Oxford); 2014 Oct; 53(10):1830-4. PubMed ID: 24850877
[TBL] [Abstract][Full Text] [Related]
40. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
Serri J; Legré R; Veit V; Guardia C; Gay AM
Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
